Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Oct 25, 2017 10:14am
194 Views
Post# 26855349

RE:RE:BKC on Agoracom

RE:RE:BKC on Agoracomronrydell, good point re Hepa not having the financial base to be the LOI. However, the Chinese gov't is very strategic and they are looking to dominate many sectors, particularly those based on IP strength leading to competitive advantages that will grow their long term economy. If Hepa has a good relationship with Chinese gov't funded banks and if Hepa is perceived as a good risk and the possibility of owning leading edge biotech IP (break through epigenetic IP) then Hepa may qualify for a significant financing package especially if the FA passes.

However, that is just (silly) long shot speculation on my part.

As the Chinese have adopted the western diet the same thing is happening to their society as in North America. Obesity continues to grow leading to CVD, DM, CKD and many other diseases. It's a big problem.

The one theme that seems consistent and just a bit under the radar (although mentioned many times) is that it does not appear that Don has a significant deal locked up with a BP or other source of financing. Many have mentioned that the FA is the key barrier at this stage but at this stage there is no evidence or hint of a deal in my opinion other than Don stating that RVX has received a LOI.

I sure hope he delivers a very positive surprise soon.
Toinv


Bullboard Posts